Clinical trials: Diabetes;Adult Onset
Diabetes, Diabetes Mellitus, Type 2
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes…
- Trial name
- DUAL™ II Japan (NCT02911948)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 38 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S
T2DM (Type 2 Diabetes Mellitus)
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.
- Trial name
- NCT05369078
- Testing
- THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Newsoara Biopharma Co., Ltd.
Type 2 Diabetes
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104…
- Trial name
- NCT00252876
- Testing
- tesaglitazar
- Where
- 277 sites in United States, Argentina and 29 more
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
This study is conducted in Europe. The aim of this observational study is to investigate the incidence of serious adverse drug reactions when using NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) for…
- Trial name
- NCT00842894
- Testing
- insulin detemir, biphasic insulin aspart 30
- Where
- North Macedonia
- Volunteers
- 3,421 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
This study looks at how faster aspart reaches and stays in the blood after injection in Chinese people with type 1 diabetes or type 2 diabetes, compared to the reference product called NovoRapid®.
- Trial name
- NCT04698018
- Testing
- Faster Aspart, Novo Rapid
- Where
- 3 sites in Germany, Hong Kong
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Hypertension, Type 2 Diabetes
Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.
- Trial name
- NCT00160160
- Testing
- eprosartan/HCTZ
- Where
- 63 sites in Canada, Denmark and 7 more
- Volunteers
- 440 people
- Sponsor
- Solvay Pharmaceuticals
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin
This study is designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD) agents and twice-daily placebo plus OAD with respect to glycemic control, as measured by hemoglobin A1c (HbA1c), in patients with…
- Trial name
- NCT00099320
- Testing
- exenatide
- Where
- 51 sites in United States, Canada and 1 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542424
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,889 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
A three part study to demonstrate the bioequivalence of a single dose of the Final Market Image (FMI) of sitagliptin/metformin 50/500, 50/850 and 50/1000 mg Fixed-Dose Combination (FDC) tablet and co-administration of…
- Trial name
- NCT00961480
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500mg, Comparator: sitagliptin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
- Trial name
- NCT07187479
- Testing
- Physiologic Insulin Resensitization (PIR)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Well Cell Global
Diabetes, Diabetes Mellitus, Type 2
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e.
- Trial name
- SUSTAIN™ 6 (NCT01720446)
- Testing
- semaglutide
- Where
- 253 sites in United States, Algeria and 19 more
- Volunteers
- 3,297 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD…
- Trial name
- SUSTAIN™ 2 (NCT01930188)
- Testing
- semaglutide, sitagliptin
- Where
- 141 sites in Argentina, Bulgaria and 16 more
- Volunteers
- 1,231 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes Mellitus, Type 2
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without…
- Trial name
- NCT06937203
- Testing
- ARO-ALK7
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 150 people
- Sponsor
- Arrowhead Pharmaceuticals
Type 2 Diabetes
Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus
Trial Title A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared to a sham control with a lifestyle…
- Trial name
- NCT04595968
- Testing
- Vestal DM Active device, Lifestyle modification
- Where
- 16 sites in United States, Ireland
- Volunteers
- 267 people
- Sponsor
- Neurovalens Ltd.
Diabetes Mellitus, Type 2
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
The purpose of this research study is to look at concentrations of GSK189075, WELLBUTRIN SR and active metabolic products in blood samples when doses of both drugs are taken by mouth. Doses are either taken alone or together.
- Trial name
- NCT00625859
- Testing
- GSK189075, Bupropion
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Specific Clinical Experience Investigation for Long-term Use of Bydureon.
To confirm the safety and efficacy of Bydureon in long-term use in Japanese patients with type 2 diabetes mellitus under actual drug use.
- Trial name
- NCT01940770
- Where
- 47 sites in Japan
- Volunteers
- 1,137 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions.
- Trial name
- NCT05714683
- Testing
- Semaglutide
- Volunteers
- 600 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers
SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia.
- Trial name
- SHR3824 (NCT02356224)
- Testing
- SHR3824
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
The purpose of this study was to evaluate the long-term safety and efficacy of SYR-322, once daily (QD), to an α-glucosidase inhibitor, three times daily (TID), administered for 40 consecutive weeks in participants who completed…
- Trial name
- NCT01263496
- Testing
- Alogliptin, Voglibose
- Volunteers
- 438 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 2
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
This study is conducted in Asia. The aim of this study is to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus.
- Trial name
- Lead-In (NCT01212133)
- Testing
- liraglutide
- Where
- India
- Volunteers
- 1,386 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.